Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYON4228 first-in-human study in relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma
NL-OMON56086Phase 2Not yet recruiting
- Sponsor
- Byondis
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of BYON4228 and rituximab in mature B-cell lymphoma and non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Byondis. Primary endpoints: Incidence of dose-limiting toxicity, Optimal biological dose and 1 more. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
BYON4228rituximab
03
Conditions
mature B-cell lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON56086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56086.